Aetna Makes Changes to National Precertification List

June 2019 ~

Effective September 1, Aetna will require precertification is required for certain new-to-market drugs.

As of September 1, 2019, precertification is required for the following:

  • Cervical laminoplasty
  • Aveed® (testosterone undecanoate)

Additionally, the following new-to-market drugs will require precertification:

  • UdenycaTM (pegfilgrastim-cbqv) — precertification effective March 1, 2019. This drug is included in the granulocyte colony-stimulating factor class.
  • Cablivi® (caplacizumab-yhdp) — precertification effective April 17, 2019.
  • Truxima® (rituximab-abbs) — precertification effective May 15, 2019. This drug is included in the immunologic agents class.

As a reminder, Aetna encourages providers to submit precertification requests at least two weeks before the scheduled services.

More information about precertification can be found under the General Information section on Aetna’s NPL page.

 

Source(s): Aetna; Aetna Office Link Updates;

 

 

AdvantEdge